In addition to sharing technical results summaries on clinicaltrials.gov and eudract.ema.europa.eu (EudraCT), Amgen has committed to publicly disclose a synopsis of each clinical study report (CSR Synopsis) for Amgen-sponsored trials included in the marketing application beginning with new product approvals in 2015. For new products filed in the U.S. and EU after January 1, 2014, CSR synopses will be posted publicly on the Amgen portal within a reasonable time after regulatory approval in the later region.

The CSR synopses will be redacted to remove commercially confidential or personally identifying patient information before posting on AmgenTrials.com.

Additionally, Amgen is also committed to publicly share available CSR Synopses retrospectively to 2004. The postings will be done in a step-wise manner by 2017.

This information is intended to satisfy public disclosure commitments and shall not be used for any other purpose. It shall also not be considered to be a claim for any marketed product. Some information in this document may differ from, or not be included in, the approved labeling for the product. Please refer to the full prescribing information for indications and proper use of the product.

To locate the CSR synopsis for a particular clinical trial, please click on the name of the product of interest below. You will be taken to a list of clinical trials by product from where you can select the particular clinical trial of interest by the study number and title. Please note the list of products will be visible as the CSR synopses are made available.

Product List

List of products alphabetized by generic name
  • ABP 215 : ABP 215
  • ABP 501 : ABP 501
  • AMG 009 : AMG 009
  • AMG 076 : AMG 076
  • AMG 102 : AMG 102
  • AMG 108 : AMG 108
  • AMG 139 : AMG 139
  • AMG 151 : AMG 151
  • AMG 167 : AMG 167
  • AMG 172 : AMG 172
  • AMG 181 : AMG 181
  • AMG 208 : AMG 208
  • AMG 220 : AMG 220
  • AMG 221 : AMG 221
  • AMG 223 : AMG 223
  • AMG 317 : AMG 317
  • AMG 319 : AMG 319
  • AMG 333 : AMG 333
  • AMG 357 : AMG 357
  • AMG 386 : AMG 386
  • AMG 401 : AMG 401
  • AMG 403 : AMG 403
  • AMG 423 : Omecamtiv Mecarbil
  • AMG 477 : AMG 477
  • AMG 479 : Ganitumab
  • AMG 487 : AMG 487
  • AMG 517 : AMG 517
  • AMG 557 : AMG 557
  • AMG 579 : AMG 579
  • AMG 595 : AMG 595
  • AMG 623 : AMG 623
  • AMG 655 : Conatumumab
  • AMG 706 : Motesanib Diphosphate
  • AMG 745 : AMG 745
  • AMG 747 : AMG 747
  • AMG 761 : AMG 761
  • AMG 780 : AMG 780
  • AMG 785 : Romosozumab
  • AMG 801 : AMG 801
  • AMG 811 : AMG 811
  • AMG 820 : AMG 820
  • AMG 827 : brodalumab
  • AMG 837 : AMG 837
  • AMG 853 : AMG 853
  • AMG 853 : Vidupiprant
  • AMG 876 : AMG 876
  • AMG 951 : dulanermin
  • anakinra : anakinra
  • blinatumomab : BLINCYTO™
  • carfilzomib : Kyprolis™
  • Cinacalcet HCl : Sensipar®
  • darbepoetin alfa : Aranesp®
  • denosumab : Prolia®
  • denosumab : XGEVA®
  • Epoetin alfa : EPOGEN®
  • Erenumab : Aimovig™
  • Etanercept : Enbrel®
  • etelcalcetide : Parsabiv™
  • evolocumab : Repatha™
  • Palifermin : Palifermin
  • Panitumumab : Vectibix®
  • Pegfilgrastim : Neulasta®
  • r-metHuGDNF : Liatermin
  • romiplostim : Nplate®
  • talimogene laherparepvec : IMLYGIC™